


Supplementary Figure S14. *In vivo* efficacy of ABT-263 in combination with established drugs against ALL-2, ALL-19 and ALL-31. ABT-263 was combined with (A) vincristine (VCR), (B) dexamethasone (DEX) or (C) *L*-asparaginase (L-ASN). Left panels for each xenograft, %HuCD45⁺ of individual mice over time; right panels for each xenograft, proportion of mice remaining event-free. Shaded areas indicate the treatment period.



Supplementary Figure S15. MCL1 protein expression at different stages of spleen extraction. Proteins were extracted as described in the Materials and Method from two spleens at three stages: (1) freshly harvested spleen and post red cell lysis, (2) splenocytes post-Ficoll separation and (2) splenocytes post-Ficoll separation and cryopreservation. HL-60 and Raji cells were included as controls.

